Quantcast

Latest Sangamo BioSciences Inc. Stories

2014-10-16 08:30:41

RICHMOND, Calif., Oct. 16, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced that Company scientists and clinicians, as well as academic collaborators, were invited speakers at three major scientific meetings in Europe and the United States. Their presentations covered a number of therapeutic uses of Sangamo's novel zinc finger protein (ZFP) technology, but were primarily focused on reviewing the progress of the Company's ZFP Therapeutic(®) program in HIV/AIDS....

2014-10-15 16:30:09

RICHMOND, Calif., Oct. 15, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) today announced that the company will release its third quarter 2014 financial results after the market closes on Wednesday, October 22, 2014. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the quarter's financial results and discuss other business matters....

2014-09-10 08:29:47

Timeline for Hemophilia B IND Application Filing Targeting Second Quarter 2015 RICHMOND, Calif., Sept. 10, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced plans to submit an Investigational New Drug (IND) application for the treatment of hemophilia B in the second quarter of 2015. This program, partnered with Shire, is the first therapeutic application of Sangamo's zinc finger nuclease (ZFN)-mediated In Vivo Protein Replacement Platform (IVPRP). Sangamo is...

2014-09-08 08:29:30

Control of Viral Load During Treatment Interruption of Antiretroviral Therapy Sustained and Ongoing for More than One Year in One Subject and Several Months in Another RICHMOND, Calif., Sept. 8, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new data demonstrating that a single infusion of Sangamo's novel ZFP Therapeutic(®), SB-728-T, resulted in sustained reduction and control of viral load (VL) in the absence of antiretroviral drugs...

2014-09-03 16:29:35

RICHMOND, Calif., Sept. 3, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(® )development programs and an overview of the company's business strategy at 9:10 am ET on Wednesday, September 10, 2014, at the 2014 Morgan Stanley Global Healthcare Conference. The conference is being held in New York....

2014-08-05 16:27:47

RICHMOND, Calif., Aug. 5, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Geoff Nichol, M.B., Ch.B., Sangamo's executive vice president of research and development, will provide an update on the progress of Sangamo's ZFP Therapeutic(® )development programs and an overview of the company's business strategy at 3:40 pm ET on Tuesday, August 12, 2014, at the 2014 Wedbush Life Sciences Management Access Conference. The conference is being held in New...

2014-08-05 08:35:04

Ranked Among the "World's Most Influential Scientific Minds" RICHMOND, Calif., Aug. 5, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced that five members of the Company's research and development team were recently named among Thomson Reuters' list of "The World's Most Influential Scientific Minds 2014", ranking among the top one percent of scientists most cited in their subject field. Among biotechnology companies, Sangamo had the highest number of scientists...

2014-07-23 16:27:46

RICHMOND, Calif., July 23, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) today reported its second quarter 2014 financial results and accomplishments. http://photos.prnewswire.com/prnvar/20130102/SF35903LOGO For the second quarter ended June 30, 2014, Sangamo reported a consolidated net loss of $7.0 million, or $0.10 per share, compared to a net loss of $5.5 million, or $0.10 per share, for the same period in 2013. As of June 30, 2014, the Company had cash, cash equivalents,...

2014-07-16 16:23:59

RICHMOND, Calif., July 16, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) today announced that the company will release its second quarter 2014 financial results after the market closes on Wednesday, July 23, 2014. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the quarter's financial results and discuss other new business...

2014-06-19 08:28:26

RICHMOND, Calif., June 19, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced the appointment of H. Stewart Parker to the Company's Board of Directors. Ms. Parker, who founded and served as President and CEO of Targeted Genetics Corporation, brings more than 30 years of experience in the biotechnology industry, including 16 years of specific experience in cell and gene therapy. http://photos.prnewswire.com/prnvar/20130102/SF35903LOGO "We are very pleased to...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related